NASDAQ:AMPH - Amphastar Pharmaceuticals Stock Price, Forecast & News

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) announced its quarterly earnings data on Thursday, November, 7th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.08 by $0.02. The business had revenue of $80.14 million for the quarter, compared to analyst estimates of $78.53 million. Amphastar Pharmaceuticals had a net margin of 15.77% and a return on equity of 5.07%. The company's revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.12 earnings per share. View Amphastar Pharmaceuticals' Earnings History.

Amphastar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Amphastar Pharmaceuticals.

3 brokers have issued 12-month price objectives for Amphastar Pharmaceuticals' stock. Their forecasts range from $22.20 to $29.00. On average, they expect Amphastar Pharmaceuticals' share price to reach $24.73 in the next year. This suggests a possible upside of 29.0% from the stock's current price. View Analyst Price Targets for Amphastar Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amphastar Pharmaceuticals.

Media headlines about AMPH stock have trended extremely negative on Monday, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amphastar Pharmaceuticals earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the near term. View News Stories for Amphastar Pharmaceuticals.

Some companies that are related to Amphastar Pharmaceuticals include PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), SAGE Therapeutics (SAGE), Zai Lab (ZLAB), Emergent Biosolutions (EBS), Myokardia (MYOK), Allakos (ALLK), Apellis Pharmaceuticals (APLS), Axsome Therapeutics (AXSM), Intercept Pharmaceuticals (ICPT), Genmab A/S (GMAB), Agios Pharmaceuticals (AGIO), Deciphera Pharmaceuticals (DCPH), Alkermes (ALKS) and Amicus Therapeutics (FOLD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), AbbVie (ABBV), Advanced Micro Devices (AMD), Cellectis (CLLS), Clovis Oncology (CLVS) and Neurocrine Biosciences (NBIX).

Amphastar Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (2.37%), Renaissance Technologies LLC (1.77%), Goldman Sachs Group Inc. (0.92%), Bank of New York Mellon Corp (0.83%), Rothschild & Co. Asset Management US Inc. (0.71%) and Marshall Wace LLP (0.63%). Company insiders that own Amphastar Pharmaceuticals stock include Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Physics & Chemistry La Applied, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi. View Institutional Ownership Trends for Amphastar Pharmaceuticals.

AMPH stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Bank of America Corp DE, Acadian Asset Management LLC, Cubist Systematic Strategies LLC, First Trust Advisors LP, State of Tennessee Treasury Department, Skandinaviska Enskilda Banken AB publ and Arizona State Retirement System. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Floyd F Petersen, Jack Y Zhang, Jason B Shandell, Richard K Prins, Rong Zhou, William J Peters and Yakob Liawatidewi. View Insider Buying and Selling for Amphastar Pharmaceuticals.

AMPH stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Goldman Sachs Group Inc., Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Bank of Montreal Can, Great West Life Assurance Co. Can, State Street Corp and Victory Capital Management Inc.. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AMPH stock can currently be purchased for approximately $19.17.

Amphastar Pharmaceuticals has a market capitalization of $899.84 million and generates $294.67 million in revenue each year. The company earns $-5,740,000.00 in net income (profit) each year or $0.21 on an earnings per share basis. Amphastar Pharmaceuticals employs 2,078 workers across the globe.View Additional Information About Amphastar Pharmaceuticals.

The official website for Amphastar Pharmaceuticals is http://www.amphastar.com/.

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]